Patent 11926665 was granted and assigned to Tesaro on March, 2024 by the United States Patent and Trademark Office.
The present disclosure provides methods of administering certain TIM-3 binding agents to patients having cancer. Dosage regimens for compositions comprising a TIM-3 binding agent are also explicitly provided.